Patent ID: 7763248
Filing Date: 2010-07-27
Classification: A61K,A61P,C07K

Abstract:
1. A method of inhibiting angiogenesis, comprising administering an antibody, or antigen-binding fragment thereof, which is a variant of monoclonal antibody HUI77 having one or more complementarity determining regions (CDRs) having an amino acid sequence differing from the corresponding CDRs of monoclonal antibody HUI77, and which has higher binding affinity for denatured collagen type I or IV over native collagen type I or IV, said antibody or antigen binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein said heavy chain variable region comprises: (i) a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 38 or the amino acid sequence of SEQ ID NO: 38 but for one or more substitutions selected from the group consisting of: (ii) a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 40 or the amino acid sequence of SEQ ID NO: 40 but for one or more substitutions selected from the group consisting of: (iii) a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 42 or the amino acid sequence of SEQ ID NO: 42 but for one or more substitutions selected from the group consisting of: wherein said light chain variable region comprises: (iv) a light chain CDR1 having the amino acid sequence of SEQ ID NO: 32 or the amino acid sequence of SEQ ID NO: 32 but for one or more substitutions selected from the group consisting of: (vi) a light chain CDR2 having the amino acid sequence of SEQ ID NO: 34 or the amino acid sequence of SEQ ID NO: 34 but for one or more substitutions selected from the group consisting of: (vi) a light chain CDR3 having the amino acid sequence of SEQ ID NO: 36 or the amino acid sequence of SEO ID NO: 36 but for one or more substitutions selected from the group consisting of: